Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION: Arsenic Trioxide TACE + IV vs TACE Alone in Unresectable HCC
NCT01861912Phase 3Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jun 2013
- Primary completion
- Jun 2016
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised trial of arsenic trioxide in hepatocellular carcinoma (HCC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Time to Progression up to 2 years. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01861912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861912.